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DOI 10.1016/j.ccr.2010.04.027SUMMARYCastration-recurrent prostate cancer (CRPC) is suspected to depend on androgen receptor (AR). The AF-1
region in the amino-terminal domain (NTD) of AR contains most, if not all, of the transcriptional activity.
Here we identify EPI-001, a small molecule that blocked transactivation of the NTD and was specific for
inhibition of AR without attenuating transcriptional activities of related steroid receptors. EPI-001 interacted
with the AF-1 region, inhibited protein-protein interactions with AR, and reduced AR interaction with
androgen-response elements on target genes. Importantly, EPI-001 blocked androgen-induced proliferation
and caused cytoreduction of CRPC in xenografts dependent on AR for growth and survival without causing
toxicity.INTRODUCTION
Androgen ablation therapy causes a temporary reduction in
prostate cancer tumor burden concomitant with a decrease in
serum prostate-specific antigen (PSA). Unfortunately, prostate
cancer will begin to grow again in the absence of androgens to
form castrate-recurrent disease (CRPC), which is characterized
before the onset of symptoms by a rising titer of serum PSA.
Most patients succumb within 2 years of rising PSA. The current
treatment for CRPC is docetaxel combined with prednisone,
which increases survival by 2 months.
Androgen receptor (AR) is suspected to play a role in CRPC.
The AR has distinct functional domains that include the ligand-
binding domain (LBD), a DNA-binding domain (DBD), and an
amino-terminal domain (NTD). AR NTD contains the AF-1 that
contributes most of the activity to the ligand-bound AR (JensterSignificance
Androgen receptor (AR) is a transcription factor that plays an
a small molecule that inhibits transactivation of the AR amino
its mechanism is unique from antiandrogens that target the C
due to gain-of-function mutations in the LBD, or expression o
to be toxic in the therapeutic dose range in vivo; and (3) curre
recurrent prostate cancer (CRPC). These findings suggest tha
for the treatment of CRPC.et al., 1991; Rundlett et al., 1990; Simental et al., 1991), rather
than AF-2 in the LBD, making the AR unique from other steroid
receptors. The AR NTD is activated by alternative pathways in
the absence of androgen (Sadar 1999; Ueda et al., 2002a,
2002b; Quayle et al., 2007). Binding of androgen to the LBD of
the AR results in its activation such that the receptor can
effectively bind to its specific DNA consensus site, termed
androgen response element (ARE), on the promoter and
enhancer regions of androgen regulated genes, such as PSA,
to initiate transcription. Evidence supporting the AR in CRPC
includes that many of the same genes that are increased by
androgens in androgen-dependent prostate cancer xenografts
become elevated in CRPC (Gregory et al., 1998). This suggests
that the AR can be activated in the absence of testicular andro-
gens in CRPC, which is consistent with the finding that nuclear
AR protein is present in secondary prostate cancer tumors (Kimimportant role in prostate cancer. We identified EPI-001 as
-terminal domain (NTD). The advantages of EPI-001 are: (1)
-terminal ligand-binding domain (LBD) and fail presumably
f constitutively active splice variants; (2) it does not appear
ntly there are no curative treatment options for castration-
t the AR NTD is a promising target to develop therapeutics
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EPI-001 Inhibits Transactivation of the AR NTDet al., 2002; van der Kwast et al., 1991). Other data supporting the
role of AR in CRPC include amplification of the AR gene (Moul
et al., 1995; Visakorpi et al., 1995), delayed onset of CRPC by
altering the timing and sequence of use of antiandrogens (Bru-
chovsky et al., 2001), and the necessity of AR for proliferation
and tumor growth (Zegarra-Moro et al., 2002; Chen et al.,
2004). Importantly, in cell culture the AR can be activated in the
absence of androgen (and absence of serum) by stimulation of
the cAMP-dependent protein kinase (PKA) pathway, inter-
leukin-6 (IL-6), growth factors (Culig et al., 1994; Nazareth and
Weigel, 1996; Sadar, 1999; Ueda et al., 2002a, 2002b), and by
bone-derived factors (Blaszczyk et al., 2004). The mechanism
of transactivation of the AR in the absence of androgens by alter-
native pathways such as cAMP/PKA, IL-6, and epidermal growth
factor involves the AR NTD (Sadar, 1999; Ueda et al., 2002a,
2002b; Blaszczyk et al., 2004; Quayle et al., 2007; Gregory
et al., 2004) and CRPC is independent of the AF-2 region in the
LBD (Dehm and Tindall, 2006). Thus, in vitro in the absence of
androgen, or in vivo in the absence of testicular androgens, the
AR NTD can be activated and is implicated in the molecular
mechanism of CRPC. Recently, naturally occurring splice vari-
ants of the AR that lack the LBD have been reported in prostate
cancer cell lines (LNCaP and 22Rv1), and also in CRPC (Dehm
et al., 2008; Guo et al., 2009; Hu et al., 2009). These mutants
are constitutively active and would not be inhibited by current
therapies that target the AR LBD such as antiandrogens and
androgen ablation therapy. Targeting the AR NTD blocks in vivo
prostate cancer tumor growth in the presence (androgen sensi-
tive) and absence of androgens (CRPC) (Quayle et al., 2007).
AR inhibitors used clinically all target the LBD. These antian-
drogens predominantly fail presumably due to poor affinity and
gain-of-function mutations in the LBD that lead to activation of
the AR by these same antiandrogens (Taplin et al., 1999).
Although the crystal structure has been resolved for the AR C-
terminal LBD, this has not been the case for the NTD due to its
high flexibility and intrinsic disorder in solution (Reid et al.,
2002), thereby hampering virtual docking drug-discovery
approaches. Here, our goal was to identify an antagonist to the
AR NTD that: (1) interacts with the NTD; (2) inhibits protein-
protein interactions with the NTD; and (3) potently reduces
CRPC tumor burden.
RESULTS
Transactivation of the AR NTD
Deletion experiments have shown that the NTD is essential for
transcriptional activity of the AR in response to ligand as well as
in the absence of ligand (Jenster et al., 1991). Thus, a small-mole-
cule inhibitor of NTD function would block AR activity regardless
of ligand. AR can be activated by androgen (ligand-dependent),
and in the absence of both serumand androgen (ligand-indepen-
dent) by forskolin (FSK), which stimulates PKA activity, or IL-6, by
transactivation of the AR NTD. We screened a library of marine
sponge extracts for inhibition of both ligand-dependent and
ligand-independent activation of the AR by blocking transactiva-
tion of the AR NTD and identified small-molecule analogs desig-
nated EPI-001 and 185-9-1. The structures of both the active
(EPI-001) and inactive analog (185-9-1) are shown in Figure 1A.
The ability of EPI-001 to inhibit transactivation of the AR NTD536 Cancer Cell 17, 535–546, June 15, 2010 ª2010 Elsevier Inc.was tested in LNCaP cells cotransfected with an expression
vector for a chimeric protein encoding amino acids 1–558 of the
human AR NTD fused to the Gal4DBD with a reporter gene con-
taining the Gal4-binding site. Androgen and the antiandrogen
bicalutamide have no effect on this chimera due to the lack of
the AR LBD in the Gal4DBD-AR1-558 chimera. 185-9-1 is an
analog of EPI-001 that has no activity in the concentration range
employed andwasusedasa control. EPI-001 reducedbothFSK-
induced and IL-6-induced transactivation of the ARNTD to base-
line levels (Figure 1B). EPI-001 had no effect on FSK-induction of
transactivation of the Gal4DBD-CREB fusion protein, which
supports that the inhibitory effects of EPI-001 are localized to
the AR NTD and do not involve the Gal4DBD. EPI-001 has an
IC50 of6 mM for inhibition of transactivation ARNTD (Figure 1C).
EPI-001 Inhibits AR Activity Regardless of Ligand
An inhibitor of AR NTD function would block the activity of the
full-length AR when activated by both ligand-dependent and
ligand-independent mechanisms. To test this, we transfected
LNCaP cells with the PSA(6.1 kb)-luciferase reporter that
contains several AREs and is dependent upon AR for induction.
LNCaP cells express endogenous AR that is activated by the
synthetic androgen, R1881, and in the absence of both serum
and androgen, by FSK or IL-6. EPI-001 blocked the induction
of PSA-luciferase activity in response to androgen (R1881) and
alternative pathways in the absence of androgen (FSK and
IL-6) (Figure 1D). EPI-001 also blocked PSA-luciferase activity
in 22RV1 cells that express both full-length AR and constitutively
active splice variant of the AR that lacks LBD (Figure 1E). EPI-001
inhibited androgen-induced ARR3-luciferase reporter activity,
that contains three repeats of the probasin ARE1 and ARE2
region, indicating that its effect was not specific to the PSA
reporter (Figure 1F). To directly test if EPI-001 could inhibit
a constitutively active deletion mutant, AR1-653, that contains
the NTD, DBD and hinge region, but not the LBD (Jenster et al.,
1991), was transfected into Cos1 cells which do not express
endogenous AR. EPI-001 inhibited this constitutively active dele-
tion mutant (Figure 1G). As expected, R1881 had no effect on
AR1-653 because it lacks the LBD. EPI-001 also inhibited wild-
type AR transfected into PC3 prostate cancer cells and exposed
to R1881 as well as the constitutive activity of AR1-653
(Figure 1H). Levels of wild-type AR and AR1-653 protein levels
from transfected cells are shown in Figure S1 (available online).
Endogenous Gene Expression
Induction of PSA and TMPRSS2 mRNAs in LNCaP cells is
dependent upon AR. To test whether EPI-001 had an effect on
endogenous gene expression, the levels of transcripts for
numerous well-characterized androgen-regulated genes were
measured in LNCaP cells. EPI-001 blocked androgen induction
of endogenous PSA mRNA (Figure 2A), TMPRSS2 mRNA
(Figure 2B), as well as 16 other well-known androgen-regulated
genes (Figure S2A). However, EPI-001 did not inhibit androgen
induction of all genes (an example is BLVRB).
AR Interaction with AREs on the DNA
Chromatin immunoprecipitation (ChIP) was used to assess if
EPI-001 prevented AR binding to endogenous AREs in the regu-
latory regions of the PSA or TMPRSS2 genes in the physiological
Figure 1. EPI-001 Blocks AR Transcriptional Activity
(A) Chemical structures of EPI-001 (BADGE.H2O.HCl) or the inactive analog 185-9-1 (BADGE.2H2O).
(B) Transactivation assays of the AR NTD were performed in LNCaP cells cotransfected with p5 3 Gal4UAS-TATA-luciferase and either AR-(1-558)-Gal4 DBD,
Gal4DBD-CREB prior to incubation with FSK or IL-6 or vehicle for 24 hr. Bicalutamide (BIC), EPI-001, or 185-9-1 were added 1h before the addition of FSK or IL-6.
(C) IC50s of EPI-001 versus 185-9-1 on AR NTD transactivation were examined in LNCaP cells with varying concentrations of EPI-001 and 185-9-1.
(D) EPI-001 inhibits both ligand-dependent and ligand-independent activation of the AR. LNCaP cells transfected with the PSA(6.1kb)-luciferase reporter and
treated with R1881, FSK, or IL-6 under serum-free conditions for 24 hr.
(E) 22RV1 cells transfected with the PSA(6.1kb)-luciferase reporter, pretreated for 1 hr with BIC or EPI-001, prior to addition of R1881 for an additional 24 hr.
(F) LNCaP cells stably transfected with ARR3-luciferase reporter were pretreated for 1 hr with EPI-001 (5 mg/ml) or 185-9-1 (5 mg/ml) before the addition of R1881
for an additional 24 hr. Bars represent the mean and standard deviation (± SD).
(G) Cos-1 cells transfected with ARR3-luciferase reporter and an expression vector for AR1-653 were treated with R1881or EPI-001 for 24 hr.
(H) PC3 cells transfected with ARR3-luciferase reporter and an expression vector for wild-type AR or AR1-653 were treated with R1881 or EPI-001. Concentra-
tions: R1881 (1 nM), FSK (50 mM), IL-6 (50 ng/ml), bicalutamide (BIC, 10 mM), EPI-001 (10 mg/ml), or 185-9-1 (10 mg/ml) unless stated otherwise. Error bars repre-
sent the mean and standard error of the mean (± SEM) in (B)–(E), (G), and (H). Student’s t test: *p < 0.05; **p < 0.01; ***p < 0.001. See also Figure S1.
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EPI-001 Inhibits Transactivation of the AR NTDcontext of chromatin structure. Both PSA and TMPRSS2 are
androgen-regulated genes with well-characterized AREs.
R1881 treatment significantly increased AR binding to AREs in
promoter (PSA-PR-ARE) and enhancer (PSA-EN-ARE) of PSA
(Figure 2C) and TMPRSS2-ARE (Figure 2D), which was signifi-
cantly inhibited by EPI-001. CBP was also recruited to PSA-
EN-ARE, PSA-PR-ARE, and TMPRSS2-ARE in response toandrogen (p < 0.01). Consistent with a decrease in AR binding
to AREs, recruitment of CBP was also significantly decreased
by EPI-001 (p < 0.05). The decrease in androgen-induced AR
interaction with AREs by EPI-001 was not due to decreased
levels of AR protein, general prevention of serine phosphoryla-
tion of AR, or prevention of AR nuclear translocation (Figures
S2B –S2E).Cancer Cell 17, 535–546, June 15, 2010 ª2010 Elsevier Inc. 537
Figure 2. EPI-001 Inhibits Endogenous Expression of Androgen-
Regulated Genes
(A and B) EPI-001 inhibits endogenous expression of PSA (A) and TMPRSS2
(B). LNCaP cells were pretreated with EPI-001 prior to incubation for 16 or
24 hr with R1881 and harvesting total RNA. Levels of PSA and TMPRSS2
mRNAs were measured by qRT-PCR and normalized to GAPDH mRNA.
Bars represent the mean ± SD.
(C) ChIP assay used LNCaP cells that were pretreated with EPI-001 (or DMSO
as the vehicle control for 1 hr) prior to the addition of R1881 for 3 and 6 hr.
Rabbit immunoglobin G (IgG) (no antibody negative control) or anti-AR anti-
body or anti-CBP antibody was used in ChIP assay. Eluted DNA fragments
were purified and used for qPCR with primers designed to amplify the PSA-
ARE site in the enhancer (PSA-EN-ARE) and promoter (PSA-PR-ARE) of
PSA locus. Error bars represent the mean ± SD.
(D) DNA from cells was also used with primers to the ARE in TMPRSS2 locus.
The percentage input of each sample was averaged from triplicates. Bars
represent the mean ± SD.
(E) EPI-001 does not inhibit other steroid hormone receptors in LNCaP cells in
response to ligand. Preg: 4-pregnene-3,20 dione (10 nM); DEX: dexametha-
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Sequence similarities of amino acids in the AR with related
human steroid receptors progesterone receptor (PR) and
glucocorticoid receptor (GR) are significant in some domains
such as the DBD. The AR NTD shares less than 15% homology
with the NTDs of PR and GR, but these receptors interact with
some of the same proteins such as CBP. Therefore, reporter
gene assays were used to determine if EPI-001 would inhibit
GR or PR transcriptional activities. Cells were cotransfected
with expression plasmids for full-length human GR, PRb, and
the relative reporter, and then treated with ethanol vehicle,
dexamethasone (GR), or 4-pregnene-3,20 dione (progesterone)
(PR). Importantly, EPI-001 did not inhibit either PRE-luciferase
or GRE-luciferase activities in response to ligand (Figure 2E).
These data provide evidence that EPI-001 does not have
general effects on transcription or translation because it did
not inhibit induction of PRE- or GRE-luciferase reporters in
response to their cognate ligands. Thus, EPI-001 appears
specific to the AR without inhibiting the transcriptional activities
of other steroid receptors.EPI-001 Blocks N/C Interaction
Ligand-dependent activity of the AR requires N/C interaction for
antiparallel dimer formation (He et al., 1999). Antiandrogens such
as bicalutamide, flutamide, and cyproterone acetate do not
stimulate this interaction on their own, and each inhibits N/C
interaction induced by androgen (Wong et al., 1993; Langley
et al., 1995; Kemppainen et al., 1999; Masiello et al., 2002).
We applied the mammalian two-hybrid system to measure N/C
interaction in CV1 cells that do not express endogenous AR.
Cells were cotransfected with expression vectors for a chimera
protein of amino acids 1–565 of the AR NTD fused to VP16
(VP16-ARTAD, the N terminus), the expression vector for the
Gal4DBD fused to the LBD of the AR (amino acids 628–919;
Gal4-ARLBD; the C terminus), and the Gal4-luciferase reporter.
As expected, there was no detectable N/C interaction in the
absence of androgen (Figure 3A, compare columns 1 and 2).
Androgen stimulated this interaction as measured by increased
luciferase activity which was blocked by bicalutamide (columns
2 to 8). Importantly, EPI-001 inhibited androgen-stimulated N/C
interaction (columns 4 and 2), whereas the inactive analog 185-
9-1 had no effect (columns 6 and 2).EPI-001 Does Not Prevent Ligand Binding
Deletion of AF-1 in the NTD kills transcriptional activity but does
not prevent ligand binding (Jenster et al., 1991). To test whether
EPI-001 affects ligand binding, we employed fluorescence
polarization to measure competition of binding of a fluoromone
to recombinant AR-LBD. Both R1881 and bicalutamide bound
to the AR-LBD as expected (Figure 3B). EPI-001 in the concen-
tration range of 0.1 nM to 100 mM did not prevent ligand-binding
as shown by not competing with binding of fluoromone. These
data suggest that EPI-001 does not interact with the LBD or
reduce ligand-binding.sone (10 nM). Error bars represent the mean ± SEM. Student’s t test:
*p < 0.05; **p < 0.01; ***p < 0.001. See also Figure S2.
Figure 3. EPI-001 Interacts with AF-1 in the NTD to Prevent Protein-
Protein Interactions
(A) EPI-001 blocks N/C interaction induced by androgen. CV1 cells transfected
with GAL4-AR DBD and/or VP16-ARTAD and Gal4-luciferase reporter were
pretreated for 1 hr with bicalutamide, EPI-001, or 185-9-1 before addition of
R1881 for 24 hr. Error bars represent the mean ± SEM, **p < 0.01.
(B) A representative competition binding curve showing inhibition of ligand
(2 nM) binding to recombinant AR-LBD (20 nM) by the antiandrogen bicaluta-
mide and agonist R1881. EPI-001 did not inhibit ligand-binding. Mixtures were
incubated for 5 hr before measurement of fluorescent polarization. Data repre-
sent the mean ± SEM, n = 3.
(C) Steady-state fluorescence emission spectra for AR-AF1 polypeptides in
buffer, buffer plus EPI-001 (2.9 mM), or buffer plus 185-9-1 (5.3 mM). In buffer,
or buffer plus 185-9-1, the steady state spectra for AR-AF1 has a distinctive
shoulder at 305 nm and a lmax for tryptophan at 343 nm.
(D) Steady-state fluorescence emission spectra for GR-AF1 in buffer, or buffer
plus EPI-001 (5.3 mM). lmax for tryptophan was 341 nm in buffer and 338 nm in
the presence of EPI-001. Spectra have been corrected for buffer effects and
normalized to the lmax for tryptophan (100%).
(E) EPI-001 prevents physical interaction between endogenous AR and CBP.
LNCaP cells were serum-starved and then exposed to R1881, IL-6, or vehicle
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in the NTD
AR-AF1 is characterized by the presence of natural disordered
structure, which adopts a more folded conformation in the pres-
ence of binding partners or the natural osmolyte TMAO. The
conformational changes in this domain can be studied by
measuring the steady-state fluorescence spectra for endoge-
nous aromatic amino acids (tyrosine and tryptophan) (Reid
et al., 2002). In buffer, the steady-state spectrum is character-
ized by a lmax for tryptophan at 343 nm and shoulder of tyrosine
emission at 305 nm (Figure 3C). In the presence of EPI-001 there
is a dramatic loss of the tyrosine shoulder and a red-shift of the
tryptophan lmax to 349 nm. These changes are consistent with
a change in the local environment surrounding the tryptophan
residues and a quenching of the tyrosine signal due to an inter-
action of EPI-001 with AR-AF1. These changes were not
observed in the presence of the inactive compound 185-9-1.
Importantly, the steady state spectrum for GR-AF1 was not
affected by EPI-001 (Figure 3D). Taken together, the data
suggest that interaction of EPI-001 with the AR-AF1 domain
alters the steady-state fluorescence emissions for tyrosine and
tryptophan through direct binding and/or a conformational
change in the polypeptide.
EPI-001 Blocks Protein-Protein Interactions with AR
CBPand its homologp300arebridging factors andCBP interacts
with theARNTD (Frønsdal et al., 1998) to potentially stabilize both
N/C interaction as well as AR binding to AREs. CBP/p300
increases AR transactivation of the AR in response to androgen
or IL-6 (Frønsdal et al., 1998; Debes et al., 2002). Ligand-depen-
dent and ligand-independent interactions between CBP and AR
were examined using endogenous complexes isolated from
LNCaP cells that were pretreatedwith EPI-001. ARwas immuno-
precipitated with CBP as expected in response to both R1881
and by IL-6 and this interaction was reduced by EPI-001
(Figure 3E). Reprobing the blot for CBP protein revealed similar
levels ofCBPwere immunoprecipitated in each lane thereby sup-
porting that EPI-001 decreased interaction of CBP with AR in
response to both R1881 and IL-6. Consistent with these data,
EPI-001 also inhibited interaction between AF-1 (AR NTD) and
CBP-CTD recombinant proteins (Figure 3F) as well as AF-1 inter-
action with the large subunit of general transcription factor TFIIF
(RAP74), a protein previously shown to interact with AF-1 in the
AR NTD (Reid et al., 2002). In the presence of EPI-001, binding
of CBP-CTD and RAP74-CTD were each impaired by 21%. In
contrast there was little or no effect on binding in the presence
of 185-9-1. Therefore, EPI-001 is capable of disrupting at least
a subset of interactions with the AR-AF1 region in the NTD.
Because EPI-001 did not block PR or GR transcriptional activity
(Figure 2E) that require CBP interaction, these data support the
potential specificity of EPI-001 for the AR NTD.for 6 hr. Whole cell lysates were precleared with mouse IgG, immunoprecipi-
tated with anti-CBP antibodies (IP), and then analyzed by immunoblotting (IB).
(F) In vitro protein-protein interactions. Immobilized AR-AF1 was incubated
with radiolabeled CBP-NTD or with RAP74-CTD polypeptides in the absence
() or presence of EPI-001 (2.54 mM) or 185-9-1 (2.66 mM). Fold-binding is
plotted relative to a BSA control (= 1) and represents the mean ± SD for at least
n = 3 independent measurements. Student’s t test: *p = 0.05 and **p = 0.02.
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Figure 4. EPI-001 Blocked AR-Dependent Proliferation
(A) LNCaP cells treated with bicalutamide (BIC) or EPI-001 for 1 hr before the addition of R1881 (0.1 nM) for 4 days. Error bars represent the mean ± SEM.
(B) LNCaP cells treated with OCM (50%) with, or without, EPI-001 for 3 days (serum-free, androgen-free, phenol red-free conditions) Error bars represent the
mean ± SD.
(C) MDA PCa 2B cells in BRFF-HPC1 (contains 0.1 nM DHT) were treated with R1881 and EPI-001 for 5 days. Error bars represent the mean ± SEM.
(D) 22RV1 cells treated for 3 days with, or without androgen, and EPI-001 or BIC. Bars represent the mean ± SEM.
(E) EPI-001 does not block proliferation of PC3 or Du145 cells treated with vehicle or EPI-001 for 3 days. Error bars represent the mean ± SD.
(F) EPI-001 does not prevent proliferation of RKO colon cancer cells treated for 3 days. Error bars represent the mean ± SD.
(G) EPI-001 does not alter proliferation of MG63 osteosarcoma cells treated for 3 days. Error bars represent the mean ± SD, t test, p > 0.05 for all cells except
LNCaP, MDA PCa 2B, and 22RV1 (p < 0.001). Proliferation was assessed by BrdU incorporation.
Cancer Cell
EPI-001 Inhibits Transactivation of the AR NTDEPI-001 Blocks AR-Dependent Proliferation
EPI-001 was next tested to examine if it had effects on prolifer-
ation that were specific to prostate cancer cells that express
AR. LNCaP cells increase proliferation in response to androgen
(0.1 nM) and in the absence of androgen (serum-free and phenol
red-free) by osteoblast-conditioned media (OCM) by a mecha-
nism dependent on AR (Blaszczyk et al., 2004; Wang et al.,
2009). EPI-001 inhibited both androgen-dependent (Figure 4A)
and androgen-independent (OCM-induced) (Figure 4B) prolifer-
ation of LNCaP cells. EPI-001 decreased proliferation of MDA
PCa2B cells (Figure 4C) and 22RV1 cells (Figure 4D), which
both express AR. EPI-001 did not block proliferation of PC3 or
DU145 human prostate cancer cells (Figure 4E, p > 0.05 t test)
that do not express functional AR and do not rely on the AR for
growth and survival. EPI-001 did not inhibit proliferation of
RKO human colon cancer cells (Figure 4F) or MG63 osteosar-
coma cells (Figure 4G). These data support the specificity of
EPI-001 for targeting the AR to block AR-dependent
proliferation.540 Cancer Cell 17, 535–546, June 15, 2010 ª2010 Elsevier Inc.In Vivo, EPI-001 Blocks the Androgen-Axis and Inhibits
Androgen-Dependent Tumor Growth
Prostate is an androgen-dependent tissue that involutes with
androgen ablation or administration of antiandrogens. In vivo
testing of inhibitors of the androgen axis can therefore be as-
sessed by measuring changes in the weight of the prostate.
Intravenous (i.v.) injection of EPI-001 (50 mg/kg body weight)
significantly reduced the weight of prostates from intact mice
compared with control-treated animals (Figure 5A). These
data are consistent with EPI-001 inhibiting the androgen axis
in mice. Similarly, LNCaP subcutaneous (s.c.) xenografts
from intact male mice treated with EPI-001 by i.v. were signif-
icantly reduced in volume (Figure 5B). Staining sections of har-
vested xenografts revealed that EPI-001 significantly reduced
proliferation (Ki67 staining) and increased apoptosis (TUNEL
staining) (Figure 5C), which was consistent with reduced tumor
growth.
To further expand our finding, we include a newly estab-
lished patient-derived prostate cancer xenograft model.
Figure 5. EPI-001 Inhibits Androgen-
Dependent Growth In Vivo
(A) Weight of prostates from intact mice treated
with EPI-001 (i.v. 50 mg/kg body weight) every
other day for a total of 10 doses. Prostates were
harvested 2 days after the last injection. EPI-001,
n = 5; DMSO, n = 6.
(B) LNCaP tumor volume decreased in intact mice
administered with EPI-001 (same protocol as in A).
Tumors were harvested 2 days after the last injec-
tion. Error bars represent the mean ± SEM. Scale
Bar = 10 mm.
(C) EPI-001 decreases proliferation (Ki67 staining)
and increases apoptosis (TUNEL staining) in s.c.
LNCaP tumors harvested from intact mice. %
Ki67 and % TUNEL positive cells were counted
in sections from three xenografts for each treat-
ment. At least 1000 cells per xenograft were
counted. Total number of cells counted: 4156
(DMSO, Ki67), 3108 (EPI-001, Ki67), 4048
(DMSO, TUNEL), and 3089 (EPI-001, TUNEL),
n = 3 tumors. Representative slides with staining
are shown.
(D) EPI-001 decreases serum PSA in intact mice
bearing LTL313 xenografts implanted under the
renal capsule. Mice were administered EPI-001
(i.v. 50 mg/kg body weight every other day) or
BIC (gavage daily with 10 mg/kg body weight) for
a duration of 20 days. n = 4 or 5.
(E) Caspase-3 staining was used for determining
the apoptotic index, whereas Ki-67 staining was
used for determining the proliferation index of
LTL313 cancer cells. EPI-001 significantly
increased apoptosis as compared with both the
control and bicalutamide. The proliferative index
was reduced by both EPI-001 and BIC.
(F) Immunohistochemistry of representative
sections of LTL313 xenografts harvested at the
duration of the experiment and stained for Ki67,
caspase-3 (Cas-3), hematoxylin and eosin (H&E),
and AR. Error bars represent the mean ± SD (C
and E). Box and whisker plots (A and D) represent
the median, minimum, and maximum. Scale bars
represent 20 mm in all micrographs.
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Figure 6. Systemic Delivery of EPI-001 Results in Cytoreduction of
CRPC without Causing Toxicity
(A) Tumor growth in SCID mice bearing s.c. tumors receiving i.v. injections of
EPI-001 or vehicle control follows the same slope as that obtained by i.t. injec-
tion. Mice received i.v. delivery of EPI-001 (50 mg/kg body weight) every other
day, or i.t. delivery (20 mg/kg body weight) every 5 days, that began 7 days
after castration. Bars represent the mean ± SEM.
(B) Photographs of xenografts treated i.v. with EPI-001 with corresponding
IHC for markers of proliferation (Ki67) and apoptosis (TUNEL). Sections of
xenografts were immunostained (diaminobenzidine with hematoxylin counter-
staining) for Ki67 and TUNEL. The box within each image is a cropped region
from the image to enable a closer view of the expression patterns.
(C) Bodyweight of animals administered EPI-001 by i.v. over the duration of the
experiment. DMSO: n = 7, p = 0.152. EPI-001: n = 10, p = 0.483. t0 = body
weight the day of 1st injection. tf = body weight 2 days after the last injection.
Bars represent the mean ± SEM.
(D)HEstainingof sectionsof liver, spleen, lung, heartandkidneyharvestedat the
duration of the experiment from hosts receiving i.v. delivery of EPI-001 (top row)
or vehicle control (bottom row). Tissues are from the same animals shown in (B).
(E) Photographs of harvested tumors from animals that received EPI-001 by i.t.
The black bar equals 10 mm. Scale bars represent 20 mm in all micrographs.
See also Figure S3.
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from an 80-year-old man diagnosed with Gleason grade 8
prostate cancer and presenting serum PSA of 17 ng/ml (see
details at http://www.livingtumorlab.ca). LTL313 is a slow-
growing tumor with a doubling time of greater than 20 days
in intact male SCID mice, making it difficult to measure
short-term treatments on tumor volume. LTL313 xenografts
express AR and serum PSA provides a sensitive measure for
biochemical responses to treatments. After just 2 weeks
of treatment, serum PSA from the EPI-001-treated group
was significantly lower than that in the control group and
comparable to levels achieved with bicalutamide (Figure 5D).
EPI-001 treated xenografts had a higher apoptotic index
compared to tumors from control-treated mice as determined
by caspase-3 staining (Figure 5E). Proliferation was low in
LTL313 as expected compared with LNCaP tumors. EPI-001
did show a trend to decrease proliferation that was borderline
significant (p = 0.056) at this short treatment time that was
limited because of frequent tail vein injections. Histology
shows LTL313 cells express AR and levels of caspase-3 and
Ki-67 in harvested tumors (Figure 5F).
In Vivo Efficacy of EPI-001 with No Apparent Toxicity
For testingwhether EPI-001would have an effect onCRPC tumor
growth,malemicebearing LNCaPs.c. xenograftswere castrated
when the tumors were 100 mm3. Within just 2 weeks, EPI-001
by i.v. reduced tumors from 100.3 ± 1.72 mm3 to 73.03 ±
29.6 mm3 (n = 10), whereas tumors in vehicle-treated animals
continued to grow from 103.2 ± 3.89 mm3 to 148.2 ± 19.39 mm3
(n = 7) (compare the red line for EPI-001 in Figure 6A with the
blue line for dimethyl sulfoxide [DMSO]). Thus, the animals
treated with EPI-001 had tumors that were less than half
the size of controls (p = 0.0028). Immunohistochemistry (IHC)
using markers for apoptosis (TUNEL) and proliferation (Ki67)
showed that i.v. delivery of EPI-001 increased apoptosis and
reduced proliferation (Figure 6B). This was consistent with cytor-
eduction of the tumors as well as in vitro analysis of apoptosis
showing at 72 hr of treatment with R1881, that LNCaP cells had
only 5.15 ± 0.89% apoptosis while EPI-001 increased this by
almost 2-fold to 9.55%± 2.27% (p = 0.01). EPI-001 did not cause
general toxicity to animals indicated by no change in animal
behavior or bodyweight (Figure 6C). Pathology reviewof sections
of lung, heart, liver, spleen, and kidney harvested from mice
receiving EPI-001 by i.v. delivery showed no signs of toxicity
(Figure 6D). Longer treatment periods of animals were feasible
by intratumoral (i.t.) injections. Animals were castrated when
tumors were 100 mm3 (mean = 131.1 ± 24.9 mm3; n = 19).
EPI-001 (20 mg/kg body weight every 5 days) significantly
reduced the tumors, even after the first injection (compare the
green line for EPI-001 with the black line for DMSO in
Figure 6A). Note that the slope of the tumor volume for i.v. and
i.t. experiments overlap. At the duration of the experiment, the
EPI-001-treated tumors were reduced to 35.4 ± 15.7 mm3,
whereas vehicle-treated tumors continued to grow and were
435.6 ± 334.9 mm3. Thus EPI-001 reduced the tumor volume
and did not just slow the growth. This suggests EPI-001 may
be potentially curative for CRPC. Harvested tumors from
animals treated with EPI-001 also tended to be less bloody in
appearance (Figure 6E). IHC and western blot analysis reveal542 Cancer Cell 17, 535–546, June 15, 2010 ª2010 Elsevier Inc.that EPI-001 did not decrease in vivo levels of AR protein
compared with levels of AR protein in vehicle-treated xenografts
(Figure S3).
In an attempt to more closely mimic human disease, we tested
whether EPI-001would be effective in castratedmice bearing or-
thotopic LNCaP xenografts. Serum PSA was used to provide an
Figure 7. EPI-001 Inhibits Serum PSA and Growth of Orthotopic
LNCaP Xenografts in Castrated Mice
(A) Mice were administered 50 mg/kg body weight EPI-001 by i.v. every other
day for a total of 8 doses. Serum PSA was measured 2 days after the last dose
when the prostates were harvested and tumor volume measured. Initial serum
PSA: 69 ± 11 (control) and 60 ± 13 ng/ml (EPI-001), p = 0.36. SerumPSA is rep-
resented as the percentage drop from the start of the experiment. Error bars
represent the mean ± SEM.
(B) Tumor volumes and photographs of representative prostates with LNCaP
tumors from mice administered DMSO or EPI-001. Bars represent the
mean ± SEM.
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again at the duration of the experiment. Initial serum PSA levels
were similar in both treatment groups (69 ± 11 versus 60 ± 13 ng/
ml, p = 0.36) prior to castration. Serum PSA was decreased by
only 22.1% ± 29.4% at the duration of the experiment in control
mice compared to 67.2 ± 24.8% in EPI-001-treated mice
(Figure 7A). These significant differences in serum PSA between
the two groups correlated to differences in tumor volume
(Figure 7B). Prostatic tumors harvested from hosts receiving
EPI-001 were approximately 62% smaller than tumors from
control mice (122.6 ± 104.9 mm3 versus 326.5 ± 125.6 mm3,
respectively, p = 0.009).Subcutaneous PC3 Xenograft Models
The LNCaP and LTL313 xenograft models reflect the majority of
clinical CRPC that express AR and are dependent on endoge-
nous AR for growth and survival.We employed PC3 human pros-
tate cancer cells that are insensitive to androgen and do not
express functional AR to provide an indication of specificity of
EPI-001. In vitro, EPI-001 did not significantly affect proliferation
of PC3 cells (Figure 4E). Male mice were castrated and random-
ized into two groups when PC3 s.c. tumors were approximately
50 mm3 (tumor volume = 56.5 ± 5.8 mm3, n = 14). Four days after
castration, the animals were treated every other day with an i.v.dose of 50 mg/kg body weight EPI-001 or matching volume of
vehicle (control, DMSO). In contrast to LNCaP xenografts, EPI-
001 did not reduce tumors (Figures 8A and 8B). These data
support that EPI-001 is specific to the AR and does not affect
cells that do not depend on functional AR for growth and survival.DISCUSSION
Current therapies that target ARLBDprovide transient responses
but do not provide cures for patients with CRPC and presumably
fail due to gain-of-function mutations in the LBD or to expression
of constitutively active splice variants lacking the LBD. The AF-1
in the NTD contributes most of the transcriptional activity to the
AR. AF-1 mutations in the NTD do not affect ligand-binding but
obliterates transcriptional activity of the AR (Jenster et al.,
1991). Drugs that target the AR NTD would block the activity of
the AR regardless of ligand. Thus, while conventional therapy
has concentrated on androgen-dependent activation of the AR
through its C-terminal LBD, our concept of blocking transactiva-
tion of the NTD for therapy of CRPC has not been previously ad-
dressed. Here we identified a lead compound for developing
drugs that can be used to delay or potentially cure CRPC. We
show that EPI-001: (1) inhibited transactivation of the AR NTD;
(2) was specific for inhibition of the AR without inhibiting PR or
GR transcriptional activities; (3) blocked induction of androgen-
regulated genes; (4) interacted with the AF-1 region in the NTD;
(5) reducedprotein-protein interactionswith theNTD; (6) inhibited
constitutively active AR1-653 that lacks the LBD; (7) reduced AR
interaction with well-characterized AREs on target genes; (8)
blocked androgen-induced proliferation; and (9) caused cytore-
duction of CRPC in xenografts dependent on AR for growth
and survival without causing toxicity.
EPI-001-related compounds were isolated from the marine
sponge Geodia lindgreni and have structural resemblance to
BADGE (Bisphenol A Diglycidic Ether), which indicates that
they may be of industrial origin. The collected sponge presum-
ably bioaccumulated the BADGE derivatives from contaminated
seawater. Approximately 20 BADGE analogs were tested in cell-
based assays to obtain additional Structure Activity Relationship
for the pharmacophore. The compound BADGE.HCl.H2O, or
EPI-001, had the most potent activity. EPI-001 and 185-9-1
(BADGE.2H2O) are harmless metabolites of bisphenol A with no
estrogenic or androgenic effects (Poole et al., 2004; Volkel et al.,
2002; Tsai, 2006; Stroheker et al., 2004). Metabolic systems
are unable to transform BADGE into bisphenol A (Poole et al.,
2004). BADGE and its chlorohydrins were examined with conclu-
sions that they are not carcinogenic or genotoxic at daily doses
well in excess of those used here (EFSA, 2004). There are noFigure 8. EPI-001 Does Not Cause Cytoreduc-
tion of PC3 Xenografts
(A) PC xenograft growth in SCID mice bearing s.c.
tumors receiving i.v. injections of EPI-001 (n = 7) or
vehicle control (n = 7). Four days after castration,
animals received 50 mg/kg body weight by tail vein
injection every other day for a total of five injections.
Tumors were harvested 2 days after the last injection.
Bars represent the mean ± SEM.
(B) Photographs of harvested tumors. Scale bars
represent 10 mm.
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BADGE for 3 months (Poole et al., 2004). Consistent with these
observations, here i.v. delivery of 50 mg/kg body weight EPI-
001 had no effects on the histology of major internal organs, or
the body weights and behavior of the animals. EPI-001 did not
significantly reduce the proliferation of cells that do not require
functional AR for growth and survival. Interestingly, doses of
250 and 1000 mg/kg body weight BADGE daily for 2 years had
mild effects on the adrenal cortex and seminiferous tubules in
males, and in females slight atrophy of the endometrium andmy-
ometrium of the ovary (Poole et al., 2004). These tissues express
AR and tend to respond to androgens (Wilson and McPhaul,
1996), thereby supporting their antagonist effects on the
androgen pathway. Consistent with those observations, here
we show that EPI-001 reduced the weight of androgen-depen-
dent prostate tissue.
BADGE.2HCl (AR-binding IC50, 19 mM) and BADGE.2H2O/
185-9-1 (AR-binding IC50, 190 mM) are suggested to bind to
the full-length AR at high concentrations by measurement of
liberated testosterone that competed with anti-testosterone
antibody and peroxidase-labeled testosterone (Satoh et al.,
2004). Those studies did not examine EPI-001 (BADG-
E.HCl.H2O), nor did they examine dissociation kinetics. The
LBD functions independent of other domains to bind ligand
(Jenster et al., 1991). However, a compound that interferes
with the NTD such as EPI-001 could affect the ligand-dissocia-
tion rate even though it does not bind to the LBD. Deletion of
the NTD increases the dissociation rate of bound ligand (Zhou
et al., 1995), and importantly N/C interaction results in slower
dissociation of bound ligand (Langley et al., 1998). Although
EPI-001 does not bind to the LBD, it may cause ligand to disso-
ciate more quickly because it blocks N/C interaction.
AR NTD is essential for AR activity and is implicated in the
underlying molecular mechanism of CRPC. In the absence of
androgen, full-length AR is activated through its NTD by factors
secreted from bone and by alternative pathways. Changes in
protein-protein interactions of the ARNTD by stimulation of alter-
native pathways may mediate a transcriptionally active receptor
in the absence of ligand. Precedence for this mechanism is
drawn from estrogen related receptors (ERR) that are activated
in the absence of ligand by interactions with steroid receptor co-
activator (SRC) and PPAR-g coactivator 1 (PGC-1) families (Xie
et al., 1999; Huss et al., 2002; Schreiber et al., 2003;Hong
et al., 1999). In the absence of ligand, crystal structure analyses
of ERRa bound to a PGC-1a peptide, and ERRg bound to a SRC-
1 or RIP-140 peptides, have shown both ERRs assume the
conformation of ligand-activated nuclear receptors (Kallen
et al., 2004; Wang et al., 2006; Greschik et al., 2002). This
suggests that agonist ligand is not an essential requirement for
the activation of receptors. The estrogen receptor (ER)-b and
chick PR are also transactivated in the absence of ligand by
the PKA pathway through enhanced protein-protein interactions
with SRC-1 and CBP (Dutertre and Smith, 2003; Rowan et al.,
2000; Tremblay et al., 1999). The AR NTD is flexible with a high
degree of intrinsic disorder with characteristics of a collapsed
disordered conformation (Lavery and McEwan, 2008). The
limited structure of the AR NTD is thought to require interactions
with other proteins to assume correct folding for further protein-
protein interactions including interactions with bridging factors544 Cancer Cell 17, 535–546, June 15, 2010 ª2010 Elsevier Inc.such as CBP and the basal transcriptional machinery for active
transcription (Reid et al., 2002). Thus an inhibitor that blocks
essential protein-protein interactions with the NTD would block
AR transcriptional activity regardless of ligand. Indeed, here we
show that EPI-001 interacts with AF-1 and inhibits essential
protein-protein interactions including CBP, RAP74, and N/C.
EPI-001 inhibited both ligand-independent and ligand-depen-
dent interaction with CBP interaction. CBP interacts with the
AR NTD (Frønsdal et al., 1998), enhances AR transcriptional
activity (Aarnisalo et al., 1998), and levels of CBP/p300 are asso-
ciated with clinical progression (Debes et al., 2003; Comuzzi
et al., 2004). CBP may stabilize N/C interactions and AR binding
to AREs. PR and GR transcriptional activities require CBP inter-
actions (Smith et al., 1996; Kamei et al., 1996) that were not
attenuated by EPI-001, which was consistent with AR-specificity
of EPI-001. Specificity of EPI-001 for AR was also supported by:
(1) lack of effect of EPI-001 on the proliferation of cells that do not
require functional AR; (2) in vivo data showing no effect of EPI-
001 on the growth of PC3 xenografts; and (3) no effects on
body weight, or histology of internal organs, of animals receiving
i.v. delivery of EPI-001. The selectivity of EPI-001 to inhibit trans-
activation of the AR NTD and attenuate AR activity through
blocking protein-protein interactions and reducing binding to
AREs has significant therapeutic potential for the treatment of
CRPC.
EXPERIMENTAL PROCEDURES
Cell Proliferation, Transfections, Luciferase Assays, and Gene
Expression Analysis
LNCaP, 22RV1, MDA PCa2b, PC3, Du145, RKO, andMG63 cells were seeded
in 96-well plates for 24 hr before pretreating for 1 hr with bicalutamide (10 mM),
EPI-001, or 185-9-1 prior to addition of 0.1 nM R1881 for LNCaP and 22RV1
cells. BrdU incorporation was measured after 4 days for LNCaP, 5 days for
MDA PCa2b, and 3 days for 22RV1 PC3, Du145, RKO, and MG63 cells using
BrdU ELISA kit (Roche Diagnostics). BRFF HPC1 media for MDA PCa2b cells
contains 0.1 nM DHT, making androgen-free conditions not possible. Trans-
fections, luciferase assays, and gene expression analysis were performed as
described previously. Details are available in the Supplemental Experimental
Procedures.
Fluorescence Polarization
The Polar Screen Androgen Receptor Competitor Assay kit (Invitrogen) was
employed according to the manufacturer’s protocol with 20 nM AR-LBD and
2nM Fluoromone. The reactions were done in 40 ml aliquots in triplicates in
Greiner 384 black clear bottom plates and fluorescence polarization read
using the Infinite M1000 (Tecan) with excitation at 530 nM and emission at
590 nM.
Coimmunoprecipitation, Chromatin Immunoprecipation, and
Immunohistochemistry
Coimmunoprecipations, chromatin-immunoprecipation assays, and immuno-
histochemistry were performed as previously described. Details are available
in Supplemental Experimental Procedures.
Animals
Six- to eight-week-old male NOD-SCID mice were maintained in the Animal
Care Facility in the Research Center of the British Columbia Cancer Agency.
All experiments involving animals conform to the relevant regulatory standards
and the experiments were approved by the University of British Columbia
Animal Care Committee.
Subcutaneous Tumors
Mice bearing subcutaneous (s.c.) tumors were castrated when tumors aver-
aged 100mm3 (LNCaP) or 50mm3 (PC3) in size. Intact animals with s.c. tumors
began treatment when tumors were approximately 50 mm3. Tumor volumes
Cancer Cell
EPI-001 Inhibits Transactivation of the AR NTDwere calculated by the formula length3width3 height3 0.5236. Tumors and
major organs were excised 5 days after the last i.t. injection or 2 days after the
last i.v. injection and prepared for western blot analyses and IHC.
Orthotopic LNCaP Xenograft
Subcutaneous LNCaP xenografts were grafted into the anterior prostates of
male mice. When serum PSA was above 40 ng/ml, animals were randomized
into two groups and animals were castrated.
LTL313 Renal Capsule Xenograft
The patient-derived prostate cancer tissue line LTL313 was maintained by
serial transplantation of subrenal capsule xenografts into male NOD-SCID
mice supplemented with testosterone (10 mg/mouse). The protocol was
approved by the Clinical Research Ethics Board of the University of British
Columbia/BC Cancer Agency. When the tumors reached an average volume
of about 50 mm3, testosterone pellets were removed and mice were randomly
distributed into three groups for treatment for control, EPI-001, and bicaluta-
mide. At the duration of the experiment, serum PSA was measured, tumors
were harvested and measured, and sections were prepared for immunohisto-
chemistry.
SUPPLEMENTAL INFORMATION
Supplemental Information includes three figures and Supplemental Experi-
mental Procedures and can be found with this article online at doi:10.1016/
j.ccr.2010.04.027.
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